6337 RESULTS
Sort By:
Las Vegas: New Partner, New Game Plan for Lou Ruvo Brain Institute Las Vegas: AD, Risk, ApoE—Tomm40 No Tomfoolery Las Vegas: Prevention Prominent at CTAD Las Vegas: 2020 Vision—AD Prevention in 11 Years? Clinical Trials on Alzheimer’s Disease 2009
A deletion in chromosome 22 points to new genetic risk factors for Parkinson's disease.
FUS, a protein tied to neurodegeneration, normally mends DNA breaks, according to a paper in Nature Neuroscience.
It's not just for neurodevelopment anymore. Death receptor 6—known for pruning axons—also trims unused connections in adulthood, hinting at a function in Alzheimer's.
Proposed preclinical stages for Alzheimer’s disease predict well who is most likely to progress to Alzheimer’s dementia.
What’s better for future treatment of Parkinson’s: patient-derived or banked iPSCs? In comparison, patient’s own come out on top.
A new RNA interference therapy for amyotrophic lateral sclerosis has some success in mice and monkeys.
In the first study of its kind, researchers found a surprisingly low incidence of Lewy body dementias in a U.S. population.
The Alzheimer’s Disease Neuroimaging Initiative has released whole genome sequences from 809 study volunteers.
Interested in Parkinson's? Apply for access to data and tissue samples, and funds to study them, from the Michael J. Fox Foundation.
By tracking Alzheimer’s research funding internationally, a new database could help sponsors coordinate research efforts.
People who carry the Huntington’s gene develop progressively abnormal brain metabolism a decade or more before diagnosis.
Clinical trials could prove the value of amyloid scans to health insurers.
An inhibitor of a cellular stress response prevents neurodegeneration in mice infected with prion protein, and might have potential in other neurodegenerative diseases.
A cancer drug-turned-Alzheimer’s prospect now appears to have potential against a third disease, reportedly protecting animal models from Parkinson’s damage.
